Next Article in Journal
Regenerating Gene Protein as a Novel Autoantigen in the Pathogenesis of Sjögren’s Syndrome
Previous Article in Journal
Antibody Reactivity of B Cells in Lupus Patients with Increased Disease Activity and ARID3a Expression
Previous Article in Special Issue
Reverse Signaling Contributes to Control of Chronic Inflammation by Anti-TNF Therapeutics
Article Menu

Export Article

Open AccessReview
Antibodies 2015, 4(4), 369-408; doi:10.3390/antib4040369

Targeting of Tumor Necrosis Factor Alpha Receptors as a Therapeutic Strategy for Neurodegenerative Disorders

1
Department of Molecular Neurobiology, Faculty of Mathematics and Natural Sciences, University of Groningen, Groningen 9747 AG, The Netherlands
2
Department of Neurology and Alzheimer Research Center, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands
3
Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA), Antwerp 2020, Belgium
4
Laboratory of Neurochemistry and Behavior, Biobank, Institute Born-Bunge, University of Antwerp, Antwerp 2610, Belgium
5
University Center of Psychiatry & Interdisciplinary Center of Psychopathology of Emotion Regulation, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Olaf Maier
Received: 15 September 2015 / Revised: 23 October 2015 / Accepted: 11 November 2015 / Published: 19 November 2015
(This article belongs to the Special Issue TNF in the Regulation of Immune Cells)
View Full-Text   |   Download PDF [1569 KB, uploaded 19 November 2015]   |  

Abstract

Numerous studies have revealed the pleiotropic functions of tumor necrosis factor alpha (TNF-α), and have linked it with several neurodegenerative disorders. This review describes the signaling pathways induced by TNF-α via its two receptors (TNFR1 and TNFR2), and their functions in neurodegenerative processes as in Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and ischemic stroke. It has become clear that TNF-α may exert divergent actions in neurodegenerative disorders, including neurodegenerative and neuroprotective effects, which appear to depend on its signaling via either TNFR1 or TNFR2. Specific targeting of these receptors is a promising therapeutic strategy for many disorders. View Full-Text
Keywords: tumor necrosis factor alpha (TNF-α); TNFR1; TNFR2; TNFR signaling pathways; neurodegenerative disorders; therapy tumor necrosis factor alpha (TNF-α); TNFR1; TNFR2; TNFR signaling pathways; neurodegenerative disorders; therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Dong, Y.; Dekens, D.W.; De Deyn, P.P.; Naudé, P.J.W.; Eisel, U.L.M. Targeting of Tumor Necrosis Factor Alpha Receptors as a Therapeutic Strategy for Neurodegenerative Disorders. Antibodies 2015, 4, 369-408.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top